Welcome to our dedicated page for Innocan Pharma news (Ticker: INNPF), a resource for investors and traders seeking the latest updates and insights on Innocan Pharma stock.
Innocan Pharma Corp. reports developments in pharmaceutical technology and consumer wellness. The company operates through Pharmaceuticals and Consumer Wellness segments, with pharmaceutical work centered on cannabinoid-based drug delivery technologies and its LPT-CBD loaded liposome platform for prolonged and controlled CBD release.
Recurring company updates include operating and financial results, clinical and regulatory disclosures for human and animal health applications, research involving pain management and epilepsy, and capital-structure or shareholder voting matters. Consumer Wellness updates relate to self-care products and the company’s interest in BI Sky Global Ltd., an online sales joint venture.
Innocan Pharma (OTC: INNPF) reported audited 2025 consolidated results with revenues of US $26.6M, a 9.6% decline versus 2024, and gross profit of US $23.9M, down 8.6%. Gross margin stayed high at 89.9%. Operating loss was US $1.255M, a 0.7% increase. Management cited improving sales trends, supply‑chain cost savings, CVM recognition for veterinary LPT technology, and progress toward a planned U.S. public offering.
Innocan Pharma (OTCQB: INNPD) announced peer-reviewed publication of a randomized, blinded, placebo-controlled crossover trial showing a single 7 mg/kg subcutaneous injection of LPT-CBD produced statistically significant pain and function improvements in dogs with osteoarthritis versus placebo.
Key results: n=8 dogs, owner-reported function improved in 100% vs 25% (p=0.0217); reductions in lameness (p=0.033) and pain (p=0.005); measurable plasma CBD up to 4 weeks; only minor, transient adverse events. Ongoing FDA discussions noted.
Innocan Pharma (OTCQB: INNPF, CSE: INNO) announced it now anticipates listing its common shares on NYSE American on or around January 30, 2026, subject to approval of its listing application and continued compliance with exchange rules. The company is conducting a concurrent offering of securities, subject to market conditions and regulatory approval, with additional details to be filed with the SEC and SEDAR+. Innocan expects OTCQB trading to continue until the close on or about January 29, 2026, after which OTCQB trading will terminate upon effectiveness of the NYSE American listing. No shareholder action is required prior to the listing.
Innocan Pharma (symbol: INNPD) announced it anticipates listing on NYSE American on or around January 7, 2026, subject to listing application approval and continued compliance with exchange rules. The company said its common shares are expected to continue trading on OTCQB until the close of market on or about January 6, 2026, after which OTCQB trading will terminate upon NYSE effectiveness. Innocan will remain listed on the Canadian Securities Exchange under INNO. Concurrently, the company is conducting a securities offering subject to market conditions and regulatory approval; additional offering details will be disclosed in SEC and SEDAR+ filings.
Innocan Pharma (CSE: INNO, FSE: IP4, OTCQB: INNPF) has announced its participation in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. This event brings together institutional investors, corporate clients, and industry professionals to showcase innovations and financial strategies.
The company will highlight its recent regulatory achievements, including FDA approval for a 505(2)(b) abbreviated pathway for human health applications, a sponsor fee waiver, and an Investigational New Animal Drug number (INAD) for animal health applications from the FDA Center for Veterinary Medicine.
Iris Bincovich, CEO of Innocan Pharma, will present at 2PM ET in the Lotus Suite West. The management team will also conduct one-on-one investor meetings throughout the day. Interested investors can register to attend and schedule meetings online.